Amedisys, Inc. filings document the company’s completed merger, common-stock delisting, and Exchange Act registration status after its transition from a Nasdaq-listed home health, hospice and high-acuity care-in-the-home company to a wholly owned subsidiary of UnitedHealth Group. The record includes Form 8-K material-event disclosures, Form 25 notices for removal from Nasdaq listing and registration, and a Form 15 covering termination or suspension of reporting obligations for its common stock.
Earlier current reports also furnished operating and financial results, supplemental financial materials, material agreements, and capital-structure items such as credit-facility termination connected with the completed transaction.
Allyson Guidroz, the Chief Accounting Officer of Amedisys Inc. (AMED), was awarded 2,015 time-based restricted stock units (RSUs) on 08/06/2025. Each RSU represents a contingent right to receive one share of the issuer's common stock and will vest 50% on August 6, 2026 and 50% on August 6, 2027, provided the reporting person remains continuously employed on those dates. The award is recorded at a $0 price in this filing.
Following the reported transaction the filing shows the reporting person beneficially owns 9,472 shares. The report references a plan statement dated June 30, 2025 and was signed on behalf of the reporting person by Jennifer Guckert Griffin on 08/08/2025.
On 7 Aug 2025 the U.S. Department of Justice and the Attorneys General of MD, IL, NJ and NY filed a Proposed Final Judgment with the U.S. District Court for Maryland. The order—agreed to by Amedisys (AMED) and UnitedHealth Group—would settle the government’s antitrust lawsuit against their June 26 2023 merger agreement (waiver dated 26 Dec 2024). If approved, the companies must divest specified assets within 75 days of an Asset Preservation/Hold-Separate order, or within 60 days after all Indiana and West Virginia clearances, whichever is later.
The judgment requires court approval under the Antitrust Procedures and Penalties Act and the merger still depends on the remaining closing conditions in the Merger Agreement. No financial results, consideration changes or new guidance were provided.
- Filing: Form 8-K, Item 8.01 – Other Events
- Ticker: AMED; Exchange: NASDAQ Global Select
- Key risks noted: potential deal termination, regulatory delays, litigation, integration distraction and inability to complete divestitures.
Implication: The settlement framework reduces regulatory uncertainty but completion risk persists until the court rules and divestiture terms are executed.
Q2 2025 snapshot: Net service revenue rose 5.2% to $621.9 m, but operating income slid 12.7% to $45.6 m as merger-related expenses jumped to $26.3 m. Net income attributable to Amedisys fell 13% to $28.1 m, driving diluted EPS down to $0.84 from $0.98 a year ago.
Year-to-date: First-half revenue climbed 4.7% to $1.22 bn. A $48.1 m gain from the Medalogix equity rollover propelled net income 92% higher to $89.1 m (EPS $2.68). Operating cash flow improved to $63.5 m, lifting cash to $337.3 m. Debt consists mainly of a $338.1 m term loan at 5.9%; the $550 m revolver remains undrawn, and total equity increased to $1.27 bn.
Balance-sheet & liquidity: Current ratio strengthened (assets $662 m vs liabilities $488 m). No covenant breaches reported after extending the credit facility maturity to 30 Jul 2027.
Strategic & regulatory: The $101-per-share merger with UnitedHealth is contested by the DOJ; trial is pencilled in for 27 Oct 2025 and the outside date extended to 31 Dec 2025. Planned divestitures to BrightSpring and Pennant depend on DOJ approval. Management highlights 68% Medicare concentration, ongoing labor tightness and audit exposure as key risks.
Amedisys Inc. (AMED) – Form 4 filing overview
Director Bruce D. Perkins reported one transaction dated 07/01/2025. Using transaction code “G” (gift), Perkins transferred 105 shares of Amedisys common stock at a stated price of $0. Following the gift, the director’s direct beneficial ownership stands at 23,992 shares.
The filing does not disclose any derivative security activity and contains no additional explanatory remarks beyond the standard signature block.
- Size of transaction: ~0.4 % of the director’s post-transaction holdings
- Insider relationship: Director (non-executive)
- Ownership form: Direct
No other material financial data, earnings information, or strategic commentary is included in this short Form 4.